Global Epidemiology of Non-Alcoholic Fatty XXXX -Meta-Analytic Assessment of Prevalence, Incidence and Outcomes.

@entity407 @entity1 @entity82 @entity101 @entity6 @entity28 @entity409 @entity1561 @entity209 @entity157 @entity285
BACKGROUND AND AIM: @entity1561 is a major cause of @entity409 worldwide. We estimated the global prevalence, incidence, progression and outcomes of @entity1561 and NASH. METHODS: Pubmed/MEDLINE were searched from 1989-2015 for terms involving epidemiology and progression of @entity1561 . EXCLUSIONS: selected groups (only morbidly @entity28 or @entity6 or pediatric), no data on @entity285 consumption or other @entity409 . Incidence of @entity157 , @entity82 , overall mortality and liver-related mortality were determined. NASH required histologic criteria. All studies were reviewed by 3 independent investigators. Analysis was stratified by region, diagnostic technique, biopsy indication and study population. We used random-effects models to provide point estimates (95% CI) of prevalence, incidence, mortality and incidence rate ratios, and meta-regression with sub-group analysis to account for heterogeneity. RESULTS: Out of 729 studies, 86 were included with a sample size of 8,515,431 from 22 countries. Global prevalence of @entity1561 is 25.24% (22.10-28.65) with highest prevalence in Middle East and South America and lowest in Africa. Metabolic comorbidities associated with @entity1561 included @entity28 [51.34% (41.38-61.20)], type 2 @entity6 [22.51% (17.92-27.89)], @entity407 [69.16% (49.91-83.46%)], @entity101 [(39.34% (33.15-45.88)]] and @entity209 [42.54% (30.06-56.05)] . @entity82 progression proportion, measured in Brunt's score, and mean annual rate of progression in NASH were 40.76% (34.69-47.13) and 0.09 (0.06-0.12). @entity157 incidence among @entity1561 @entity1 was 0.44/1000 @entity1 -years (0.29-0.66). Liver-specific mortality and overall mortality among @entity1561 and NASH were 0.77/1000 @entity1 -years (0.33-1.77) and 11.77/1000 @entity1 -years (7.10-19.53), 15.44/1000 @entity1 -years (11.72-20.34) and 25.56/1000 @entity1 -years (6.29-103.80). Incidence Risk Ratios for liver-specific and overall mortality for @entity1561 were 1.94 (1.28-2.92) and 1.05 (0.70-1.56). CONCLUSIONS: As the global epidemic of @entity28 fuels metabolic conditions, the clinical and economic burden of @entity1561 will become enormous.f This article is protected by copyright. All rights reserved.
